Skip to main content
Sign In
 

Timothy A. McKinsey, Ph.D.

Associate Professor Associate Division Head for Translational Research


  
Timothy A. McKinsey, Ph.D.
 

Associate Professor
Associate Division Head for Translational Research
Division of Cardiology
University of Colorado Denver
12700 E 19th Avenue, Room 8014A
Aurora CO 80045
 
303-724-5476 (work)
303-464-7314 (home)
303-437-9553 (cell)
timothy.mckinsey@ucdenver.edu

 

Date and Place of Birth

 
March 18, 1968
            Springfield, Missouri
 
Marital Status
 
Married with three children
 
Education
 
1986 - 1990: B.S., Biology, University of Missouri, Columbia
1993 - 1998: Ph.D., Microbiology and Immunology (with Dr. Dean Ballard), Vanderbilt University, Nashville, TN; Molecular Mechanisms of T Lymphocyte Activation
           
Experience and Honors
 
University of Missouri
1990 - 1993: Research Associate (with Dr. Mark Hannink), Department of Biochemistry, University of Missouri, Columbia; Neoplastic Transformation by the c-Rel Proto-Oncogene Product
 
Vanderbilt University
            1996: Teaching Assistant, Vanderbilt University Medical Microbiology Course
            1996 - 1997: Trainee, National Institutes of Health Program in Cellular, Biochemical, and             Molecular Sciences
1997:  Recipient, Sidney P. Colowick Award for Most Outstanding Graduate Student, Department of Microbiology and Immunology, Vanderbilt University School of Medicine
 
University of Texas Southwestern Medical Center
1998 - 8/2002: Postdoctoral Fellow (with Dr. Eric Olson), Department of Molecular Biology, University of Texas Southwestern Medical Center at Dallas; Transcriptional Control of Muscle Differentiation and Growth
            1999 - 8/2002:  Recipient, Pfizer Fellowship from the Life Sciences Research Foundation
           
            University of Colorado
8/2002 - present: Adjunct Assistant Professor, Department of Molecular, Cellular, and             Developmental Biology, University of Colorado at Boulder
7/2003 - present: Adjunct Assistant Professor, University of Colorado Cardiovascular             Institute, Denver, Colorado
2002 - 2006: Lecturer, Department of Molecular, Cellular, and Developmental Biology core course for graduate students
2007 - 2009: Lecturer, MCDB 4201, Department of Molecular, Cellular, and Developmental Biology “From Bench to Bedside” course for undergraduate students
 
Colorado State University
2009: Lecturer, MGT450, College of Business “Biomedical Entrepreneurship” course for graduate students
 
Myogen, Inc./Gilead Colorado, Inc.
8/2002 - 1/2004: Scientist I, Myogen, Inc., Westminster, CO
8/2002 – 8/2008: Project Team Leader, Kinase Inhibitor for Heart Failure, Myogen, Inc./Gilead Colorado, Inc. (Myogen acquired by Gilead Sciences in 4Q 2006)
-guided project from target discovery through lead optimization; project was a   component of the Myogen/Novartis collaboration
1/2004 - 1/2005: Scientist II, Myogen, Inc.
1/2004 – 12/2009: Group Leader, In Vitro Biology, Gilead Colorado, Inc.
-recruited and managed a team of 18 scientists (6 Ph.D., 12 B.S./M.S.) focused on    small molecule drug discovery for cardiovascular diseases
-responsibilities included: target validation, lead discovery and optimization, pharmacodynamic marker discovery and in vitro and ex vivo evaluation of in-licensing candidates
1/2005 - 07/2006: Project Team Leader, Nuclear Enzyme Inhibitor for Heart Failure, Myogen, Inc.;
                   -project was component of the Myogen/Novartis collaboration
1/2005 - 1/2007: Scientist III, Myogen, Inc.
1/2007 - 1/2009: Senior Research Scientist II, Gilead Colorado, Inc.
1/2009 – 12/2009: Associate Director, Biology, Gilead Colorado, Inc.  (Gilead Colorado closed 12/2009)

 

Publications

 
1. Diehl, J.A., McKinsey, T.A., and M. Hannink (1993) Differential pp40IkBb inhibition of DNA binding by rel proteins. Mol. Cell. Biol. 13:1769-1778.
      
2. Sorkin, A., McKinsey, T. A., Shih, W., Kirchhausen, T., and G. Carpenter (1995) Stoichiometric interaction of the epidermal growth factor receptor with the clatherin-associated protein complex AP-2.  J. Biol. Chem. 270:619-625.
 
3. Brockman, J.A., Scherer, D.C., McKinsey, T.A., Hall, S.M., Qi, X., Lee, W.Y., and D.W.   Ballard (1995) Coupling of a signal response domain in IkBa to multiple pathways for NF-      kB activation. Mol. Cell. Biol. 15:2809-2818.
 
4. Rottjakob, E.M., Sachdev, S., Leanna, C.A., McKinsey, T.A., and M. Hannink (1996) PEST-dependent cytoplasmic retention of v-rel by IkBa: evidence that IkBa regulates cellular    localization of c-rel and v-rel by distinct mechanisms.  J. Virol. 70:3176-3188.
 
5. McKinsey, T.A., Brockman, J.A., Scherer, D.C., Al-Murrani, S.W., Green, P.L.,  and D.W.            Ballard (1996) Inactivation of IkBb by the tax protein of human T-cell leukemia virus: a    potential mechanism for the constitutive induction of NF-kB. Mol. Cell. Biol. 16:2083-2090.
 
6. Chu, Z.L., McKinsey, T.A., Liu, L., Qi, X., and D.W. Ballard (1996) Basal phosphorylation of the PEST domain in IkBb regulates its functional interaction with the c-rel proto-oncogene product. Mol. Cell. Biol. 16:5974-5984.
 
7. Sachdev, S., Diehl, J.A., McKinsey, T.A., Hans, A., and M. Hannink (1997) A threshold    nuclear level of the v-rel oncoprotein is required for transformation of avian lymphocytes.         Oncogene 14:2585-2594.
 
8. Chu, Z.L., McKinsey, T.A., Liu, L., Gentry, J.J., Malim, M.H., and D.W. Ballard (1997)     Suppression of tumor necrosis factor-induced cell death by inhibitor of apoptosis c-IAP2 is           under NF-kB control. Proc. Natl. Acad. Sci. U.S.A. 94:10057-10062.
 
9. McKinsey, T.A., Chu, Z.L., and D.W. Ballard (1997) Phosphorylation of the PEST domain of       IkBb regulates the function of NF-kB/IkBb complexes.  J. Biol. Chem. 272:22377-22380.
 
10. Lu, J., McKinsey T.A., Xu, H., Wang, D-Z., Richardson, J.A., and E.N. Olson (1999) FOG-2,     a cardiac and brain-enriched cofactor for GATA transcription factors. Mol. Cell. Biol. 19: 4495-4502.
 
11. Meguro, T., Hong, J.C., Asai, K., Takagi, G., McKinsey, T.A., Olson, E.N., and S.F. Vatner (1999) Cyclosporine attenuates pressure-overload hypertrophy in mice while enhancing            susceptibility to decompensation and heart failure. Circ. Res. 84:735-740.
 
12. McKinsey, T.A., and E.N. Olson (1999) Cardiac hypertrophy: sorting out the circuitry.     Curr. Op. in Gen. & Dev. 9:267–274.
 
13. Jo, H., Zhang, R., Zhang, H., McKinsey, T.A., Shao, J., Beauchamp, R.D., Ballard, D.W., and P. Liang (2000) NF-kB is required for H-ras oncogene induced abnormal cell tumorigenesis. Oncogene 19:841-849.
 
14. Lu, J., McKinsey, T.A., Nicol, R.L., and E.N. Olson (2000) Signal-dependent activation of the myocyte enhancer factor-2 transcription factor by dissociation from histone deacetylases.            Proc. Natl. Acad. Sci. U. S. A. 97:4070-4075.
 
15. Wu, H., Naya, F.J., McKinsey, T.A., Mercer, B., Shelton, J.M., Chin, E.R., Simard, A.R.,             Michel, R.N., Bassel-Duby, R., Olson, E.N., and R.S. Williams (2000) MEF2 responds to multiple calcium-regulated signals in the control of skeletal muscle fiber type. EMBO J.            19:1963-1973.
 
16. Passier, R., Zeng, H., Frey, N., Naya, F.J., Nicol, R.L., McKinsey, T.A., Overbeek, P.,      Richardson, J.A., Grant, S.R., and E.N. Olson (2000) CaM kinase signaling induces cardiac          hypertrophy and activates the MEF2 transcription factor in vivo. J. Clin. Invest. 105:1395-1406.
 
17. Lu, J., McKinsey, T.A., (co-first authors), Zhang, C.L., and E.N. Olson (2000)     Regulation       of skeletal myogenesis by association of the MEF2 transcription factor with class        II histone deacetylases. Mol. Cell. 6:233-244.
 
18. Frey, N., McKinsey, T.A., and E.N. Olson (2000) Decoding calcium signals involved in cardiac growth and function. Nat. Med. 6:1221-1227.
 
19. McKinsey, T.A., Zhang, C.L., Lu, J., and E.N. Olson (2000) Signal-dependent nuclear export of a histone deacetylase regulates muscle differentiation. Nature 408:106-111.
 
20. Yang, J., Rothermel, B., Vega, R.B., Frey, N., McKinsey, T.A., Olson, E.N., Bassel-Duby, R., and R.S. Williams (2000) Independent signals control expression of the calcineurin inhibitory proteins MCIP1 and MCIP2 in striated muscles. Circ. Res. 87:E61-68.
 
21. McKinsey, T.A., Zhang, C.L., (co-first authors) and E.N. Olson (2000) Activation of the            myocyte enhancer factor-2 transcription factor by calcium/calmodulin-dependent protein kinase-stimulated binding of 14-3-3 to histone deacetylase 5. Proc. Natl. Acad. Sci. U. S. A. 97:14400 - 14405.
 
22. Zhang, C.L., McKinsey, T.A., Lu, J.R., and E.N. Olson (2001) Association of COOH-     terminal-binding protein (CtBP) and MEF2-interacting transcription repressor (MITR)          contributes to transcriptional repression of the MEF2 transcription factor. J. Biol. Chem.       276:35-39.
 
23. Rothermel, B.A., McKinsey, T.A., Vega, R.B., Nicol, R.L., Mammen, P., Yang, J., Antos, C.L., Shelton, J.M., Bassel-Duby, R., Olson, E.N., and R.S. Williams (2001) Myocyte-enriched calcineurin-interacting protein, MCIP1, inhibits cardiac hypertrophy in vivo.  Proc. Natl. Acad. Sci. U. S. A. 98:3328-3333.
 
24. McKinsey, T.A., Chu, Z.L., and D.W. Ballard (2001) Transcription factor NF-kB regulates inducible CD83 gene expression in activated T lymphocytes. Mol. Immunol. 37:783-788.
 
25. Zhang, C.L., McKinsey, T.A., and E.N. Olson (2001) The transcriptional co-repressor MITR is a signal-responsive inhibitor of skeletal myogenesis.  Proc. Natl. Acad. Sci. U. S. A. 98:7354-7359.
 
26. McKinsey, T.A., Zhang, C.L., and E.N. Olson (2001) Control of muscle development by dueling HATs and HDACs.  Curr. Op. in Gen. & Dev. 11:497-504.
 
27. McKinsey, T.A., Zhang, C.L., and E.N. Olson (2001) Identification of a signal-responsive            nuclear export sequence in class II histone deacetylases.  Mol. Cell. Biol. 21: 6312-6321.
 
28. McKinsey, T.A., Zhang, C.L., and E.N. Olson (2002) The MEF2 transcription factor: a     calcium-dependent regulator of cell division, differentiation, and growth.  TiBS. 27: 40-47.
 
29. Antos, C.L., McKinsey, T.A., Frey, N., Kutschke, W., McAnally, J., Shelton, J.M., Richardson, J.A., Hill, J.A., and E.N. Olson (2002) Activated glycogen synthase kinase-3b suppresses cardiac hypertrophy in vivo. Proc. Natl. Acad. Sci. U. S. A. 99:907-912.
 
30. Zhang, C.L., McKinsey, T.A., Chang, S. Antos, C.L., Hill, J.A., and E.N. Olson (2002) Class II histone deacetylases act as signal-responsive repressors of cardiac hypertrophy. Cell 110: 479-488.
 
31. Zhang, C.L., McKinsey, T.A., and E.N. Olson (2002) Association of class II histone deacetylases with heterochromatin protein 1: potential role for histone methylation in control of muscle differentiation. Mol. Cell. Biol. 22: 7302-7312.
 
32. McKinsey, T.A., Zhang, C.L., and E.N. Olson (2002) Signaling chromatin to make muscle.  Curr. Op. in Cell Biol. 14:763-772.
 
33. Antos, C.L., McKinsey, T.A., (co-first authors), Dreitz, M., Hollingsworth, L.M., Zhang, C.L., Schreiber, K., Rindt, H., Gorczynski, R.J., and E.N. Olson (2003) Dose-dependent blockade to cardiomyocyte hypertrophy by histone deacetylase inhibitors.  J. Biol. Chem. 278:28930-28937.
 
34. Bush, E., Fielitz, J., Melvin, L., Martinez-Arnold, M., McKinsey, T.A., Plichta, R., and E.N. Olson (2004) A small molecular activator of cardiac hypertrophy uncovered in a chemical screen for modifiers of the calcineurin signaling pathway. Proc. Natl. Acad. Sci. U S A. 101:2870-2875.

35. McKinsey, T.A. and E.N. Olson (2004) Cardiac histone acetylation: therapeutic opportunities abound.  TiGS 20:206-213. 
 
36. McKinsey, T.A., and E.N. Olson (2004)  Dual roles of histone deacetylases in the control of cardiac growth. Novartis Found. Symp. 259:132-141.
 
37. Vega, R.B., Harrison, B.C., Meadows, E., Roberts, C.R., Papst, P.J., Olson, E.N., and T.A. McKinsey (2004) Protein kinases C and D mediate agonist-dependent cardiac hypertrophy through nuclear export of histone deacetylase 5. Mol. Cell Biol. 24:8374-8385.
 
38. Chang, S., McKinsey, T.A. (co-first authors), Zhang, C.L., Richardson, J.A., Hill, J., and E.N. Olson (2004) Histone deacetylases 5 and 9 govern responsiveness of the heart to a subset of stress signals and play redundant roles in heart development. Mol. Cell Biol. 24:8467-8476.
 
39. Harrison, B.C., Roberts, C.R., Hood, D.B., Sweeney, M., Gould, J.M., Bush, E.W., and T.A. McKinsey (2004) The CRM1 nuclear export receptor controls pathological cardiac gene expression.  Mol Cell Biol. 24:10636-10649.
 
40. McKinsey, T.A., and E.N. Olson (2005) Toward transcriptional therapies for the failing heart: chemical screens to modulate genes.  J. Clin. Invest. 115:538-546.
 
41. Parra, M., Kasler, H., McKinsey, T.A., Olson, E.N., and E. Verdin (2005) Protein kinase D1 phosphorylates HDAC7 and Induces its nuclear export after TCR activation.  J. Biol. Chem. 280:13762-13762.
 
42. McKinsey, T.A., and E.N. Olson (2005) Regulation of muscle gene expression by histone deacetylases. In: Histone deacetylases: Transcriptional regulation and other functions; Humana Press Inc.
 
43. McKinsey, T.A., Kuwahara, K., Bezprozvannaya, S., and E.N. Olson (2006)  Class II histone deacetylases confer signal responsiveness to the ankyrin-repeat proteins ANKRA2 and RFXANK.  Mol. Biol. Cell. 17:438-447.
 
44. Matthews, S.A., Liu, P., Spitaler, M., Olson, E.N., McKinsey, T.A., Cantrell, D.A., and A.M. Scharenberg (2006) Essential role for protein kinase D family kinases in the regulation of class II histone deacetylases in B lymphocytes.  Mol. Cell. Biol. 26:1569-1577.
 
45. Wu, X., Zhang, T., Bossuyt, J., Li, X., McKinsey, T.A., Dedman, J.R., Olson, E.N., Chen, J., Brown, J.H., and D.M. Bers (2006) Local InsP3-dependent perinuclear Ca2+ signaling in cardiac myocyte excitation-transcription coupling.  J. Clin. Invest. 116:675-682.
 
46. Huynh, Q.K., and T.A. McKinsey (2006) Protein kinase D directly phosphorylates histone deacetylase 5 via a random sequential kinetic mechanism. Arch. Biochem. Biophys. 450:141-148.
 
47. Harrison, B.C., Kim, M.S., van Rooij, E., Plato, C.F., Papst, P.J., Vega, R.B., McAnally, J.A., Richardson, J.A., Bassel-Duby, R., Olson, E.N., and T.A. McKinsey (2006) Regulation of cardiac stress signaling by protein kinase D1. Mol. Cell. Biol. 26:3875-3888. 
 
48. Bush, E.W., Hood, D.B., Papst, P.J., Chapo, J.A., Minobe, W., Bristow, M.R., Olson, E.N., and T.A. McKinsey (2006) Canonical transient receptor potential channels promote cardiomyocyte hypertrophy through activation of calcineurin signaling. J. Biol. Chem. 281:33487-33496.
 
49. Olson, E.N., Backs, J., and T.A. McKinsey (2006) Control of cardiac hypertrophy and heart failure by histone acetylation/deacetylation. Novartis Found. Symp. 274:3-12; discussion 13-9, 152-5, 272-276.
 
50. McKinsey, T.A. (2007) Derepression of pathological cardiac genes by members of the CaM kinase superfamily. Cardiovasc Res. 73:667-677.
 
51. McKinsey, T.A., and D.A. Kass (2007) Small molecule therapies for cardiac hypertrophy: moving beneath the cell surface. Nat. Rev. Drug Discov. 6:617-635.
 
52.  Xu, X., Ha, C.H., Wong, C., Wang, W., Hausser, A., Pfizenmaier, K., Olson, E.N., McKinsey, T.A., and Z.G. Jin (2007) Angiotensin II stimulates protein kinase D-dependent histone deacetylase 5 phosphorylation and nuclear export leading to vascular smooth muscle cell hypertrophy. Arterioscler. Thromb. Vasc. Biol. 27:2355-2362.
 
53.  Renthal, W., Maze, I., Krishnan, V., Covington, H.E., Xiao, G., Kumar, A., Russo, S.J., Graham, A., Tsankova, N., Kippin, T.E., Kerstetter, K.A., Neve, R.L., Haggarty, S.J., McKinsey, T.A., Bassel-Duby, R., Olson, E.N., and E.J. Nestler (2007) Histone deacetylase 5 epigenetically controls behavioral adaptations to chronic emotional stimuli. Neuron 56:517-529.
 
54.  Backs, J., Backs, T., Bezprozvannaya, S., McKinsey, T.A., and E.N. Olson (2008)
Histone deacetylase 5 acquires calcium/calmodulin-dependent kinase II responsiveness by oligomerization with histone deacetylase 4. Mol. Cell. Biol. 28:3437-3445.
 
55.  Ha, C.H., Wang, W., Jhun, B.S., Wong, C., Hausser, A., Pfizenmaier, K., McKinsey, T.A., Olson, E.N., and Z.G. Jin (2008) Protein kinase D-dependent phosphorylation and nuclear export of histone deacetylase 5 mediates vascular endothelial growth factor-induced gene expression and angiogenesis.  J. Biol. Chem. 283:14590-14599.
 
56.  Kim, M.S., Fielitz, J., McAnally, J., Shelton, J.M., Lemon, D.D., McKinsey, T.A., Richardson, J.A., Bassel-Duby, R., and E.N. Olson (2008) Protein kinase D1 stimulates MEF2 activity in skeletal muscle and enhances muscle performance. Mol. Cell. Biol. 28:3600-3609.
 
57.  YY1 protects cardiac myocytes from pathologic hypertrophy by interacting with HDAC5.
Sucharov, C.C., Dockstader, K. and T.A. McKinsey (2008) Mol. Biol. Cell. 19:4141-4153.
 
58. Suppression of HDAC nuclear export and cardiomyocyte hypertrophy by novel irreversible inhibitors of CRM1. Monovich, L., Koch, K.A., Burgis, R., Osimboni, E., Mann, T., Wall, D., Gao, J., Feng, Y., Vega, R.B., Turner, B.A., Hood, D.B., Law, A., Papst, P.J., Koditek, D., Chapo, J.A., Reid, B.G., Melvin, L.S., Pagratis, N.C. and T.A. McKinsey (2009) Biochim. Biophys. Acta. 1789:422-431.
 
59.  Targeting histone deacetylases for heart failure.  Bush, E.W. and T.A. McKinsey (2009) Expert Opin. Ther. Targets 13:767-784.
 
60.       Increased phosphorylation-dependent nuclear export of class II histone deacetylases in failing human heart.  Calalb, M.B., McKinsey, T.A., Newkirk, S., Huynh, K., C.C., Sucharov, C.C. and M.R. Bristow (2009) Clinical and Translational Science 2: 325-332.
 
61.  Protein acetylation in the cardiorenal axis: the promise of histone deacetylase inhibitors.  Bush, E.W. and T.A. McKinsey (2010) Circulation Research 106:272-284.

 

62.       A novel kinase inhibitor establishes a predominant role for protein kinase D as a cardiac class IIa histone deacetylase kinase.  Monovich, L., Vega, R.B., Meredith, E., Miranda, K., Rao, C., Capparelli, M., Lemon, D.D., Phan, D., Koch, K.A., Chapo, J.A., Hood, D.B., and T.A. McKinsey (2010) FEBS Lett. 584:631-637.
 
63.       Protein kinase C-related kinase targets nuclear localization signals in a subset of class IIa histone deacetylases. Harrison, B.C., Huynh, K., Lundgaard, G.L., Helmke, S.M., Perryman, M.B., and T.A. McKinsey (2010) FEBS Lett. 584:1103-1110.
 
64.  Identification of Orally Available Naphthyridine Protein Kinase D Inhibitors. Meredith, E.L., Ardayfio, O, Beattie, K., Dobler,M.R., Enyedy, I., Gaul, C., Hosagrahara, V., Jewell, C., Koch, K., Lee, W.,  Lehmann, H., McKinsey, T.A., Miranda, K., Pagratis, N., Pancost, M., Patnaik, A., Phan, D., Plato, C., Qian, M., Rajaraman, V., Rao, C., Rozhitskaya, O., Ruppen, T., Shi, J., Siska, S.J., Springer, C., van Eis, M., Vega, R.B., vonMatt, A., Yang, L., Yoon, T., Zhang, J-H.,Zhu, N., and L.G. Monovich (2010) Journal of Med. Chem. In Press.
 
65.  Potent and selective thyromimetics lacking structural similarity to thyroid hormone regulate cardiac myosin heavy chain expression.  Bush, E.W., McQuire, L., Gamber, G.G., Ksander, G., Jain, R.K., Sung, M.J., Tallarico, J.A., Tomassi, Vega, R.B., Shetty, S., Plato, C., Pitts, K., Chapo, J., Schreiber, K., Kronlage, J., McKinsey, T.A., Castonguay, L.A., Pagratis, N., Todd, J., Glascock, C., Peng, Y., Gorczynski, R.J., and L.S. Melvin (2009) Submitted.
 
66.  Preliminary studies of 3,5-diarylazoles as novel and selective inhibitors of protein kinase D.  Gamber, G., Meredith, E., Zhu, Q., Yan, W., Rao, C., Capparelli, M., Burgess, R., Enyedy, I., Zhang, J.H., Soldermann, N., Koch, K., Pagratis, N., Hosagrahara, V., Vega, R.B., McKinsey, T.A., and Lauren Monovich (2009) Submitted.
 

Patents

 
       1. Olson, E.N., Lu, J.R., and T.A. McKinsey (2001) Methods and compositions relating to histone deacetylase 4 and 5 regulation of cardiac gene expression.  United States Patent No. 6,632,628.
 
2. Bristow, M.R., Long, C., McKinsey, T.A. and E.N. Olson (2003) Inhibition of histone deacetylase as a treatment for cardiac hypertrophy.  United States Patent No. 6,706,686. 
 
3. McKinsey, T.A., Olson, E.N., and R.B. Vega (2004) Inhibition of protein kinase C-m (protein kinase D; PKD) as a treatment for cardiac hypertrophy and heart failure. WO  2004112763. 
 
4. McKinsey, T.A., Olson, E.N., Harrison, B.C., Rybkin, I., and S. Helmke (2005) Inhibition of protein kinase C-related kinase (PRK) as a treatment for cardiac hypertrophy and heart failure. WO  2005074941.
 
5. Bush, E.W., Gorczynski, R.J., Koch, K., and McKinsey, T.A. (2007) Use of inhibitors of the ubiquitin proteasome pathway as a method of increasing contractility of the heart. US  2007015777 
 
6. T.A. McKinsey (2005) Inhibition of nuclear export as a treatment for cardiac hypertrophy and heart failure. WO  2005097088.
 
7.      Backs, J., Harrison, B.C., Huynh, K., McKinsey, T.A., Olson, E.N., and N. Pagratis
(2007) Methods of treatment and uses for CaMKII and its interaction with HDACs and calpain. WO  2007059533.
 
Editorial Boards
 
Current Drug Discovery Technologies
Recent Patents on Cardiovascular Drug Discovery
 
Invited Speaker
 
2000: Department of Microbiology and Immunology/Interdisciplinary Graduate Program, Vanderbilt University Medical Center, Nashville, TN
2001: Department of Cellular and Molecular Physiology, Pennsylvania State College of Medicine, Hershey, PA
2001:
Gordon Conference on Myogenesis, Il Ciocco, Italy
2001: Gordon Conference on Calcium Signaling, Oxford, England
2001: 5th Annual Meeting of the Heart Failure Society of America, Washington, D.C.
2002: 24th Annual Meeting of the International Society for Heart Research, Madison, WI
2002: 6th Annual Meeting of the Heart Failure Society of America, Boca Raton, FL
            2002: American Heart Association (AHA) Scientific Sessions, Chicago, IL
2003: Department of Pharmacology, University of Colorado Health Sciences Center, Denver
2003: Annual Experimental Biology Meeting, San Diego, CA
2003: Second Annual Symposium of the GlaxoSmithKline Research & Education Foundation for Cardiovascular Disease, Philadelphia, PA
2004: 8th Annual Meeting of the Heart Failure Society of America, Toronto
2005: University of Missouri Symposium on Science in Industry
2006: 3rd Annual AHA Symposium on Basic Cardiovascular Sciences, Keystone, CO
2006: 10th Annual Meeting of the Heart Failure Society of America, Seattle
2006: University of South Dakota School of Medicine
2007: World Congress of the International Society for Heart Research, Bologna, Italy
2007: Keystone Symposium on Histone Deacetylases, Snowmass, CO
2007: Ohio St. University Program in Molecular, Cellular and Developmental Biology, Columbus, Ohio
2008: University of Colorado Health Sciences Center Alternative Careers in Science seminar series
2009: Colorado State University Department of Cell and Molecular Biology
2009: University of Florida Center for Epigenetics
 
Research Support
 
1R43HL74544-01A1 – 01/04 – 01/05*
NIH/NHLBI - $100,000
Phase I SBIR
Development of Kinase Inhibitors to Treat Cardiac Hypertrophy and Heart Failure
*Funds returned to NIH following signing of collaborative agreement between Myogen and Novartis